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Abstract
Introduction
Hispanic women in the United States have an elevated risk of cer-
vical cancer, but the existing literature does not reveal why this
disparity persists.
Methods
We performed a retrospective cohort analysis of 17,828 low-in-
come women aged 21 to 64 years seeking care at Oregon com-
munity health centers served by a hosted, linked electronic health
record during 2009 through 2013. We assessed the odds of having
had Papanicolaou (Pap) tests and receiving human papillomavirus
(HPV) vaccine, by race/ethnicity, insurance status, and language.
Results
Hispanic women, regardless of pregnancy status or insurance, had
greater odds of having had Pap tests than non-Hispanic white wo-
men during the study period. English-preferring Hispanic women
had higher odds of having had Pap tests than Spanish-preferring
Hispanic  women  (OR,  2.08;  95%  confidence  interval  [CI],
1.63–2.66) but lower odds of having received HPV vaccination
(OR, 0.21; 95% CI, 0.12–0.38). Uninsured patients, regardless of
race/ethnicity, had lower odds of HPV vaccine initiation than in-
sured patients did. Once a single dose was received, there were no
significant racial/ethnic differences in vaccine series completion.
Conclusion
In this sample of low-income women seeking care at Oregon com-
munity health centers, we found minimal racial/ethnic disparities
in the receipt of cervical cancer prevention services. Inequities by
insurance status, especially in the receipt of HPV vaccine, persist.
Community health center–based care may be a useful model to ad-
dress racial/ethnic disparities in prevention, but this model would
need further population-wide study.
Introduction
Hispanic women in the United States have an increased risk of
cervical cancer (1,2) despite the existence of screening techniques
that have longstanding, demonstrated effectiveness (3) and a vac-
cine that protects against the primary cause of cervical cancer —
infection with certain subtypes of human papillomavirus (HPV)
(4). Regular Papanicolaou (Pap) testing of women aged 21 to 65
years detects early cervical changes associated with HPV; treat-
ment prevents progression to invasive cervical cancer (3). It is un-
certain which biological, social, or behavioral factors might factor
most heavily in these cancer prevention disparities. Health ser-
vices research on the uptake of cervical cancer preventive services
(Pap testing and HPV vaccination) among Hispanic women has
largely been survey-based and has yielded varying and sometimes
contradictory results. Many studies show that Hispanic women are
less likely than other women to receive recommended Pap tests
(5–7) and suggest numerous factors that may affect this disparate
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utilization (6,8–12). However, other survey-based studies show
that Hispanic women may use Pap tests more than non-Hispanic
white women (2,13,14). There is similarly conflicting information
about disparities in HPV vaccination uptake; some studies show
lower vaccine initiation or completion rates among Hispanic wo-
men compared with non-Hispanic white women (15–17), some
studies do not show disparities in certain Hispanic subpopulations
(15),  and some studies suggest impacts of insurance and other
factors on the uptake of HPV vaccine (17,18). With some excep-
tions (17,18), most of this work is survey-based, which has signi-
ficant limitations in the study of preventive service use (19–22).
Survey responses can be influenced by social desirability bias,
and, because they are often administered at a single time point,
surveys often provide limited information about services and asso-
ciated factors over time.
We aimed to compare the use of cervical cancer prevention ser-
vices (ie, Pap testing and HPV vaccination initiation and comple-
tion) among Hispanic women and non-Hispanic white  women
who sought care at community health centers (CHCs) with linked
electronic health records (EHRs) during a 5-year period in Ore-
gon. This investigation was novel in its use of objective EHR data,
its 5-year study period, and its incorporation of language and in-
surance status as moderators.
Methods
This was a retrospective observational cohort study of factors as-
sociated with cervical cancer screening and HPV vaccination re-
ceipt among female CHC adult patients who had a clinic visit dur-
ing 2009 through 2013. We used EHR data from OCHIN (not an
acronym), a 501(c)(3) network that centrally hosts an Epicare plat-
form to more than 300 CHCs nationwide covering more than 2
million patients (23–25). The Oregon CHCs included in this ana-
lysis provide comprehensive primary care to low-income patients
in rural, urban, and suburban communities across Oregon, encom-
passing preventive services and acute, chronic, mental or behavi-
oral, and obstetric care (23). Participants were Hispanic women or
non-Hispanic white women aged 21 to 64 years who accessed 1 of
the 23 OCHIN-affiliated CHCs in Oregon at least once (26) dur-
ing 2009 through 2013 and had income of less than 100% of the
federal poverty level at every visit (n = 17,828). Women with a
documented hysterectomy were excluded from the analysis.
Variables
Variables were race/ethnicity (Hispanic vs non-Hispanic white),
preferred language (Spanish vs English), insurance status (insured
with Medicare, Medicaid, and/or private insurance at any point
during the study period vs no insurance). We used Hispanic and
non-Hispanic white as ethnicity categories, because these reflect
the specific federally reported categories collected by CHCs; we
acknowledge the limits of these ethnic categories in describing this
population.
Outcomes were receipt of a Pap test during the study period, re-
ceipt of 1 HPV vaccine dose during the study period, and receipt
of a complete 3-dose HPV vaccine series during the study period.
We chose these outcomes because they are clinically relevant (1
vaccine dose offers protection against HPV [27]), and because
these benchmarks may represent 2 phases of care quality: 1) ini-
tial engagement with and 2) completion of a recommended pre-
ventive service that takes a period of time. Initial recommenda-
tions for HPV vaccine were made by the Advisory Committee on
Immunization Practices (ACIP) in 2007 (28), and we were able to
capture  data  on  all  vaccinations  in  our  network  during  2007
through 2013. For some analyses, we restricted the sample to wo-
men aged 21 to 29, who, among our overall cohort, might conceiv-
ably receive HPV vaccine (even if older than the recommended
maximum age of 26). Our study period was largely before wide-
spread implementation of the 2012 recommendation for HPV test-
ing along with cervical cytology evaluation in some populations,
so this testing was not included in our outcomes.
Covariates were age at start of the study period, number of CHC
visits during the study period (categorized as 1, 2–5, or >5 visits
over 5 years), and pregnancy during the study period. CHC use
served as a proxy for comorbidity in general (29); we also adjus-
ted for pregnancy, which could have associations with our out-
come.
Statistical analysis
Race/ethnicity and insurance disparities in receipt of cervical can-
cer screening among the overall sample (N = 17,828) were ex-
amined by comparing the odds of receiving at least 1 Pap test and
receiving HPV vaccination among 4 cohorts: insured Hispanic
women, uninsured Hispanic women, insured non-Hispanic white
women, and uninsured non-Hispanic white women. Multivariable
logistic  regression  was  used  to  estimate  adjusted  odds  ratios
(aORs) and 95% confidence intervals (CIs). Because patients in
the same CHC are more likely to be similar to each other in re-
ceipt of services than they are to patients in other CHCs (hence, no
longer independent), the Huber–White estimator of the standard
error (30) was used to estimate 95% CIs for the adjusted odds ra-
tios to account for clustering of patients within their home clinic
(the CHC that the patient visited most often). Secondary analyses
examined the associations between cervical cancer prevention ser-
vices and patients’ preferred language (among Hispanic women
only; N = 3,384) and among subsets of women aged 21 to 29 (for
HPV vaccine). All secondary analyses also used similar multivari-
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able logistic regression with clustered standard errors similar to
the primary analysis. Statistical tests were 2-sided; significance
was set at a P value less than .05. Statistical analyses were per-
formed in 2016–2017 using R version 3.3.2 (The R Foundation).
The institutional review board of Oregon Health and Science Uni-
versity approved this study.
Results
Of our total study population (N = 17,828), the largest cohort was
insured non-Hispanic white women (n = 10,063) (Table). Insured
patients (Hispanic women and non-Hispanic white women) were
more likely than uninsured patients to be in the youngest (21–29
y) age bracket (43% and 37%, respectively). Most Hispanic wo-
men identified Spanish as their preferred language. Both insured
cohorts were more likely than the uninsured cohorts to have more
than 5 visits during the study period (Hispanic women, 58%; non-
Hispanic white women, 49%), and both uninsured cohorts were
more likely than the insured cohorts to have 2 to 5 visits during the
study period (Hispanic women, 43%; non-Hispanic white women,
44%). Though all cohorts had high percentages of women who
were not pregnant during the study period, insured Hispanic wo-
men were the largest proportion of pregnant women (47%).
Overall, 55% of the patients in our cohort received a Pap test dur-
ing the study period: 65% of Hispanic women and 51% of non-
Hispanic white women. After adjusting for age, CHC use, and
pregnancy status, insured Hispanic women still had higher odds of
receiving a Pap test during the study period compared with in-
sured non-Hispanic white women (OR, 1.35; 95% CI, 1.22–1.50).
Uninsured Hispanic women also had higher odds of having re-
ceived a  Pap test  during the  study period (OR,  1.29;  95% CI,
1.18–1.42) compared with insured non-Hispanic white women.
Uninsured non-Hispanic white women had lower odds of receiv-
ing a Pap test during the study period than insured non-Hispanic
white women (OR, 0.48; 95% CI, 0.44–0.53). Nonpregnant wo-
men had similar patterns, odds ratios, and significance as all wo-
men.
Overall HPV initiation rates in the subset of women aged 21 to 29
years were approximately 4%, and completion rates were approx-
imately 1.4%. Insured Hispanic women did not differ signific-
antly from insured non-Hispanic white women in their receipt of
at least 1 HPV vaccine dose (Figure). Both uninsured groups had
lower odds of receiving at least 1 HPV vaccine dose than the in-
sured non-Hispanic white group (Hispanic women: OR, 0.31; 95%
CI, 0.17–0.55; and non-Hispanic white women: OR, 0.24; 95% CI,
0.12–0.48). Among women who received at least 1 dose of HPV
vaccine, we found no significant difference among the study co-
horts in completion of the vaccine series, although the sample size
for subpopulation was small (n = 268).
Figure.  Adjusted odds ratios (ORs)  and 95% confidence intervals  (CIs)  of
receiving at least 1 dose of human papillomavirus (HPV) vaccine compared
with adjusted odds ratio of completing an HPV vaccine series among women
aged  21  to  29  years,  by  race/ethnicity  and  insurance  status,  Oregon,
2009–2013. Multivariable logistic regression was used to estimate odds of
receiving at least 1 HPV vaccine dose, by race/ethnicity and insurance status
relative to insured non-Hispanic white women (x-axis; n = 6,346). Then, among
those who initiated an HPV regimen, we performed another multivariable
logistic  regression  to  estimate  odds  of  completing  a  HPV  regimen  by
race/ethnicity and insurance status relative to insured non-Hispanic white
women (y-axis; n = 268). Both models adjusted for pregnancy and number of
health center visits (1, 2–5, >5) during the study period. For both models, we
estimated 95% confidence intervals  using robust  Huber–White sandwich
estimators of the standard error to account for clustering of patients within
home clinic (the community health center that the patient visited most often).
Abbreviation: NHW, non-Hispanic white.
 
In evaluating the impact of preferred language among Hispanic
women aged 20 to 29 years, English-preferring Hispanic women
had more than double the odds of receiving a Pap test (OR, 2.08;
95% CI, 1.63–2.66) but lower odds of receiving the HPV vaccine
(OR, 0.21; 95% CI, 0.12–0.38) than Spanish-preferring Hispanic
women (both P < .001).
Discussion
This analysis was a novel investigation of use of cervical cancer
preventive services in a large cohort of low-income women in
Oregon CHCs. Our findings had several patterns. Overall, the rate
of receipt of Pap tests during the 5-year study period (55%) was
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lower than the national rate of receipt of cervical cancer screening
(81%) (31). However, national surveys do not focus on a low-in-
come safety-net population and do not verify self-report with ob-
jective confirmation of tests (31), so direct comparison may not be
appropriate. In our analysis, Hispanic women (insured and unin-
sured) had increased odds of receiving a Pap test than insured non-
Hispanic white women, even when they were not pregnant. This
finding is consistent with some previous research and may sug-
gest that barriers to receiving cervical screening in this population
are not directly associated with ethnicity. However, Hispanic wo-
men whose language preference was Spanish had a lower screen-
ing rate than Hispanic women whose language preference was
English. The lower odds of Pap testing among Spanish-speaking
Hispanic  women was surprising given the  language resources
available  in  CHCs  and  previous  findings  in  our  network  that
showed no difference in other preventive services between Eng-
lish- and Spanish-speaking Hispanics (32,33). This finding needs
further research to understand the role of language preference in
Pap test uptake.
The HPV vaccination rate among adult women aged 21 to 29 in
our network was 4% overall and 3.2% among Hispanic women;
these low rates were likely attributable to our inclusion of adults
only in the early years of vaccine introduction. Uninsured patients
had lower odds of receiving at least 1 HPV vaccine, regardless of
whether they were Hispanic women or non-Hispanic white wo-
men. Once a single dose was received, there were no observed dis-
parities between cohorts in completion of vaccination, although ef-
fect sizes were large for Hispanic women in the direction of His-
panic women having higher odds of completion. This completion
of vaccination suggests that lack of insurance is the main barrier to
vaccine uptake, a finding that has also been noted in children eli-
gible for this vaccine (17). Spanish language preference was asso-
ciated with higher odds of receiving vaccine, demonstrating that
Spanish preference is not a barrier to the receipt of other vaccines,
as other analyses of adult vaccination have noted (32).
Uninsured non-Hispanic white women demonstrated low rates of
utilization of services overall. The reasons for these low rates are
not certain, but the low rates have been observed in analyses of
other services in our network (32–34) and are likely due to addi-
tional, unmeasured barriers in this population.
Our study has several limitations. We were unable to definitively
capture data on services outside of our network, though evidence
suggests patients in our network tend not to receive services else-
where (35). Our study of HPV vaccine receipt showed low rates
overall, limiting the conclusions we can draw from these data and
highlighting additional need for research on access to cervical can-
cer prevention. Our data set did not include adolescents or chil-
dren, so we could not evaluate HPV vaccination rates among these
populations, but because we were able to capture data on all vac-
cinations from 2007 onward (when the ACIP approved HPV vac-
cination), we were able to thoroughly evaluate HPV vaccination in
this adult cohort. Although we were able to account for insurance,
income (our population was low-income), race/ethnicity, and pre-
ferred language, there may be social factors (education, employ-
ment, marital status) that we were unable to measure but that af-
fect receipt of vaccine. Our approach did not consider a temporal
analysis and assumes a negligible temporal trend in Pap testing in
these CHCs from 2009 through 2013. This assumption may be
feasible because our study period largely predated the widespread
use  of  HPV cotesting  (a  sentinel  policy  and practice  change).
More recent data are needed to replicate our study findings after
the introduction of HPV cotesting. Our analysis measures the ac-
cess to period-appropriate prevention services, not general ad-
vances in prevention approach. We were limited to broad federal
race/ethnicity categories because more granular categories are not
routinely collected in the OCHIN EHR system. An analysis of
Hispanic subgroups might yield more nuanced results. Immigra-
tion status may also affect use of care, and many patients in our
network likely are immigrants (32,34,36). However, we were not
able to definitively assess immigration status, so it remains a limit-
ation of our analysis. Finally, our data set did not include data on
Pap results, which might have affected receipt of services in mean-
ingful ways and could have been used to study women who devel-
op cervical cancer and the characteristics that put them at higher
risk.
In our objective, longitudinal EHR-based analysis, insured and un-
insured Hispanic women seen at Oregon CHCs had increased odds
of receiving Pap tests compared with insured non-Hispanic white
women. Uninsured patients had lower odds of starting the HPV
vaccine series, but once initiated, there were no racial/ethnic or in-
surance disparities in vaccine series completion. Spanish language
preference (rather than English preference) among Hispanic wo-
men was associated with decreased odds of Pap testing but in-
creased odds of receiving any HPV vaccine. Policy makers should
understand that among adult Hispanic women with access to a
CHC, cervical cancer prevention services seemed to be equitable,
although this observation needs further study in a wider sample of
patients. Efforts to ensure that access to cervical cancer preven-
tion services is available to all are warranted.
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Table
Table. Patient Characteristics in Study of Use of Cervical Cancer Prevention Services Among Low-Income Women, by Race/Ethnicity and Insurance Status, Oregon,
2009–2013
Characteristic
N (Column %)
Hispanic Women Insured
(n = 2,381)
Hispanic Women
Uninsured (n = 2,452)
Non-Hispanic White
Women Insured
(n = 10,063)
Non-Hispanic White
Women Uninsured
(n = 2,932)
Total
(n = 17,828) P Valuea
Age, y
21–29 1,032 (43) 766 (31) 3,709 (37) 839 (29) 6,346 (36)
<.001
30–39 815 (34) 985 (40) 2,574 (26) 701 (24) 5,075 (28)
40–49 337 (14) 424 (17) 2,001 (20) 766 (26) 3,528 (20)
50–64 197 (8) 277 (11) 1,779 (18) 626 (21) 2,879 (16)
Language
Spanish 1,550 (65) 2,192 (89) 22 (0) 37 (1) 3,801 (21)
<.001English 804 (34) 246 (10) 9,485 (94) 2,829 (96) 13,364 (75)
Other 27 (1) 14 (1) 556 (6) 66 (2) 663 (4)
Office visits during 2009–2013
1 271 (11) 525 (21) 1,803 (18) 1,126 (38) 3,725 (21)
<.0012–5 726 (30) 1,045 (43) 3,285 (33) 1,286 (44) 6,342 (36)
>5 1,384 (58) 882 (36) 4,975 (49) 520 (18) 7,761 (44)
Pregnant anytime during 2009–2013
No 1,271 (53) 2,060 (84) 8,381 (83) 2,816 (96) 14,528 (81)
<.001
Yes 1,110 (47) 392 (16) 1,682 (17) 116 (4) 3,300 (19)
a P values were calculated by using a χ2 test.
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